PDCD1 and neoplasm: PD-L1 inhibitors (atezolizumab, durvalumab) selectively bind to PD-L1 on tumor cells, reverse T cell inhibition by directly blocking PD-L1 binding to PD-1, and enhance T cell-mediated immune responses [119].